Gemcitabine HCl
别名: NSC 613327 HCl,LY-188011 HCl
中文名称:盐酸吉西他滨
目录号:S1149 Purity: 99.96%
Gemcitabine HCl是一种DNA synthesis抑制剂,作用于PANC1,MIAPaCa2,BxPC3和Capan2细胞,IC50分别为50 nM, 40 nM, 18 nM和12 nM。
CAS: 122111-03-9
客户使用Selleck的Gemcitabine HCl发表文献183篇
- Drug Resist Updat, 2023 71:101005
- Nat Cell Biol, 2023 25(2):309-322
- Mol Cancer, 2022 21(1):112
- Cell, 2021 184(25):6119-6137.e26
- Mol Cancer, 2021 20(1):97
- Cancer Cell, 2019 35(3):519-533
- Int J Biol Sci, 2024 20(4):1389-1409
- Phytomedicine, 2024 155377
- NPJ Precis Oncol, 2024 8(1):246
- Cell Oncol (Dordr), 2024 10.1007/s13402-024-00939-5
- iScience, 2024 27(6):110027
- Int J Mol Sci, 2024 25(6)3211
- Neoplasia, 2024 47:100951
- STAR Protoc, 2024 5(2):103090
- Nat Commun, 2023 14(1):3450
- Cell Rep Med, 2023 S2666-3791(23)00156-8
- Proc Natl Acad Sci U S A, 2023 120(11):e2122352120
- Cell Death Dis, 2023 14(4):295
- Chin Med J (Engl), 2023 10.1097/CM9.0000000000002816
- iScience, 2023 10.1016/j.isci.2023.108169
- Chin Med, 2023 18(1):61
- J Biol Chem, 2023 10.1016/j.jbc.2023.105385
- Molecules, 2023 28(2)805
- J Tradit Complement Med, 2023 13(1):39-50
- bioRxiv, 2023 2023.03.27.534412
- Nat Commun, 2022 13(1):6623
- J Clin Invest, 2022 132(24)e151604
- Nucleic Acids Res, 2022 50(5):2681-2699
- Acta Pharm Sin B, 2022 12(3):1339-1350
- J Exp Clin Cancer Res, 2022 41(1):312
- Cancer Res, 2022 82(4):721-733
- Cancer Res, 2022 canres.0218.2021
- Cell Death Dis, 2022 13(5):497
- Cell Prolif, 2022 10.1111/cpr.13237
- Cell Biol Toxicol, 2022 10.1007/s10565-022-09746-w
- Mol Cell Proteomics, 2022 21(12):100438
- NPJ Breast Cancer, 2022 8(1):44
- Biochem Pharmacol, 2022 203:115166
- Mol Cancer Ther, 2022 21(2):347-358
- Front Pharmacol, 2022 13:1032975
- Front Pharmacol, 2022 13:1007429
- Int J Mol Sci, 2022 23(10)5532
- J Pers Med, 2022 12(2)258
- Biomedicines, 2022 10(5)1162
- Mol Carcinog, 2022 10.1002/mc.23401
- Life Sci Alliance, 2022 5(4)e202101157
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- World J Gastroenterol, 2022 28(32):4620-4634
- Dis Model Mech, 2022 dmm.049109
- PLoS One, 2022 17(4):e0266476
- Hematol Oncol, 2022 10.1002/hon.3007
- Anim Cells Syst (Seoul), 2022 26(4):148-157
- Anticancer Res, 2022 42(10):4679-4687
- J Ginseng Res, 2022 46(5):636-645
- Nat Commun, 2021 12(1):1602
- Nat Commun, 2021 12(1):4917
- Cancer Res, 2021 canres.1337.2021
- Cell Death Dis, 2021 12(8):772
- Cell Death Dis, 2021 12(1):72
- Br J Cancer, 2021 10.1038/s41416-021-01639-9
- Br J Cancer, 2021 10.1038/s41416-021-01658-6
- Oncogene, 2021 10.1038/s41388-020-01634-z
- Oncogene, 2021 10.1038/s41388-021-01992-2
- Oxid Med Cell Longev, 2021 2021:6673828
- Cancer Cell Int, 2021 21(1):646
- Int J Mol Sci, 2021 22(13)6825
- Biomed J, 2021 44(6):694-708
- Cancers (Basel), 2021 14(1)5
- Cancers (Basel), 2021 13(17)4405
- Cancers (Basel), 2021 13(11)2539
- Cancers (Basel), 2021 13(13)3367
- Cancers (Basel), 2021 13(3)527
- Neoplasia, 2021 23(7):643-652
- Front Oncol, 2021 11:750259
- Molecules, 2021 26(19)5858
- Sci Rep, 2021 11(1):10181
- Immunol Lett, 2021 242:8-16
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Hum Cell, 2021 34(6):1911-1918
- Cancer Med, 2021 10.1002/cam4.3739
- Invest New Drugs, 2021 10.1007/s10637-020-01003-3
- J Pharm Biomed Anal, 2021 198:114025
- Chem Biol Drug Des, 2021 10.1111/cbdd.13977
- BMC Urol, 2021 21(1):96
- Transl Cancer Res, 2021 10(3):1368-1377
- Clin Cancer Drugs, 2021 8(1):50-56
- Nat Commun, 2020 11(1):3018
- Nat Commun, 2020 24;11(1):1975
- Nat Commun, 2020 10;11(1):2935
- Nat Commun, 2020 12;11(1):2971
- Nat Commun, 2020 14;11(1):1825
- Clin Cancer Res, 2020 27 pii: clincanres
- Mol Syst Biol, 2020 16(2):e8664
- Oncogene, 2020 10.1038/s41388-020-1364-7
- Int J Mol Sci, 2020 21(23)E9034
- Am J Cancer Res, 2020 10(10):3302-3315
- Cancers (Basel), 2020 12(12)E3816
- Cancers (Basel), 2020 15;12(4) pii: E974
- J Biol Chem, 2020 1 pii: jbc
- Neoplasia, 2020 22(1):22-32
- Mediators Inflamm, 2020 2020:8567320
- Sci Rep, 2020 15;10(1):337
- Sci Rep, 2020 10(1):18489
- Cancer Res Treat, 2020 10.4143/crt.2020.585
- Food Chem Toxicol, 2020 147:111919
- BMC Cancer, 2020 20(1):984
- J Biochem Mol Toxicol, 2020 e22621
- Med Sci Monit, 2020 26:e922703
- Am J Transl Res, 2020 12(6):2827-2842
- Anticancer Res, 2020 40(7):3659-3667
- bioRxiv, 2020 2020/9/20.4.7.30734
- Genes Chromosomes Cancer, 2020 10.1002/gcc.22884
- J Immunother Cancer, 2019 7(1):199
- J Control Release, 2019 305:89-100
- Int J Biol Sci, 2019 15(9):1771-1786
- Cell Prolif, 2019 52(1):e12514
- Cells, 2019 8(8)
- Cancer Sci, 2019 110(1):334-344
- Nanomedicine (Lond), 2019 14(15):1971-1989
- Cancers (Basel), 2019 11(12)E1835
- Cancers (Basel), 2019 11(12)E2042
- Biosci Rep, 2019 10.1042/BSR20192358
- BMC Cancer, 2019 19(1):604
- Invest New Drugs, 2019 10.1007/s10637-019-00839-8
- Exp Ther Med, 2019 18(1):550-558
- Nat Commun, 2018 13;9(1):2720
- Nat Commun, 2018 9(1):2434
- Cancer Res, 2018 78(19):5656-5667
- J Adv Res, 2018 15:59-68
- Mol Ther Nucleic Acids, 2018 13:472-482
- Cell Chem Biol, 2018 25(6):705-717
- Oncogene, 2018 37(44):5843-5857
- Oxid Med Cell Longev, 2018 2018:2360427
- Oxid Med Cell Longev, 2018 2018:9482018
- Sci Signal, 2018 11(540)eaat0229
- Apoptosis, 2018 23(5-6):343-355
- Mol Cancer Ther, 2018 17(12):2676-2688
- Int J Mol Sci, 2018 19(2)
- Int J Mol Sci, 2018 19(10)
- Cancers (Basel), 2018 10(5)
- J Biol Chem, 2018 293(3):984-994
- Neoplasia, 2018 20(8):826-837
- Pharm Res, 2018 35(8):154
- Dig Dis Sci, 2018 63(12):3367-3375
- Cancer Biomark, 2018 10.3233/CBM-181182
- Oncol Lett, 2018 15(5):6107-6114
- Anticancer Res, 2018 38(4):1967-1977
- Cancer Lett, 2017 411:106-116
- Cell Death Dis, 2017 8(10):e3129
- Cell Death Dis, 2017 8(5):e2770
- Br J Cancer, 2017 116(3):324-334
- Mol Oncol, 2017 11(9):1130-1142
- FEBS J, 2017 284(2):222-236
- Oncotarget, 2017 8(35):58417-58429
- J Cell Mol Med, 2017 21(9):2055-2067
- PLoS One, 2017 12(11):e0188859
- Acta Biochim Biophys Sin (Shanghai), 2017 49(7):573-580
- Cancer Res, 2016 76(13):3978-88
- J Pineal Res, 2016 60(1):27-38
- Cancer Lett, 2016 380(2):434-41
- Antiviral Res, 2016 126:69-80
- Am J Pathol, 2016 186(6):1537-46
- PLoS One, 2016 11(6):e0158617
- Tumour Biol, 2016 37(9):12731-12742
- Sci Transl Med, 2015 7(284):284ra57
- Biomedicine & Pharmacotherapy, 2015 73:123-8
- Cancer Sci, 2015 106(1):9-17
- Mol Cancer Ther, 2015
- Eur J Pharmacol, 2015 10.1016/j.ejphar.2015.03.064
- PLoS One, 2015 10(4):e0123901
- Anticancer Drugs, 2015 26(6):612-9
- Nucleic Acids Res, 2014 42(10):6436-47
- Clin Cancer Res, 2014 20(12):3187-97
- J Immunol, 2014 192(9):4273-83
- Mol Pharmacol, 2014 85(3):408-19
- Pancreas, 2014 44(1):144-151
- Freien Universit, 2014 Christian K?hler
- Cell Death Dis, 2013 4:e742
- Cancer Immunol Immun, 2013 62(2):383-91
- Biochemistry, 2013 52(40):7050-9
- Sci Signal, 2011 1(4):352-65
- Pancreas, 2011 40(5):730-9
化学信息&溶解度
分子量 | 299.66 |
分子式 | C9H11F2N3O4.HCI |
CAS号 | 122111-03-9 |
Smiles | C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F.Cl |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
Water : 59 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : Insoluble Water : 59 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : Insoluble Water : 60 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : Insoluble Water : 30 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
Saline
浓度:47.5mg/ml
(158.51mM)
操作示例:以 1 mL工作液为例,取 47.5 mg产品加入1 mL saline中,混合均匀。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。